145209-64-9

Upstream product

• 100-63-0 phenylhydrazine 
• 408336-30-1 ethyl 4-chloro-5-methoxyquinoline-3-carboxylate 
• 220844-53-1 2-[(2-bromo-5-methoxy-phenylamino)methylene]malonic acid diethyl ester 
• 161405-25-0 ethyl 8-bromo-5-methoxy-4-oxoquinolin-3-carboxylate 
• 161405-26-1 ethyl 4-hydroxy-5-methoxyquinoline-3-carboxylate 
• 59557-92-5 2-bromo-5-methoxyaniline 
• 5344-78-5 4-bromo-3-nitroanizole 

Downstream Products

• 145209-65-0 9-Hydroxy-2-phenyl-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one 

Relevant academic research and scientific papers

High affinity central benzodiazepine receptor ligands. Part 2: Quantitative structure-activity relationships and comparative molecular field analysis of pyrazolo[4,3-c]quinolin-3-ones

A large series of 2-aryl(heteroaryl)-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones (PQ, 106 compounds), carrying appropriate substituents at the quinoline and N2-phenyl rings, were designed, prepared and tested as central benzodiazepine recepto

Computer-Aided Molecular Modeling, Synthesis, and Biological Evaluation of 8-(Benzyloxy)-2-phenylpyrazoloquinoline as a Novel Benzodiazepine Receptor Agonist Ligand

Using computer-aided conformational analysis, based on molecular dynamics simulation, cluster analysis, and Monte Carlo techniques, we have designed and synthesized compounds in which a benzyloxy substituent has been incorporated into a series of pyrazoloquinoline benzodiazepine receptor (BZR) ligands.Earlier studies had shown that the benzyloxy group could act as part of the agonist pharmacophoric determinant in the β-carboline ring system.Furthermore, the agonist β-carboline had been correlated with a binding site orientation and volume fit for an agonist 6-phenylimidazobenzodiazepine carboxylate.The present study was undertaken to determine whether the benzyloxy substituent could be used as an agonist pharmacophoric descriptor for the phenylpyrazoloquinolin-3-one BZR ligands.The results of a determination of GABA shift ratios for the synthetic ligands indicate that 8-(benzyloxy)-2-phenylpyrazoloquinolin-3-one can be predicted to be an agonist at the BZR.